Standard
Hungry Bone Syndrome-Like State Following Denosumab in a Patient with Multiple Myeloma
The administration of denosumab, a high-potency monoclonal antibody used to manage bone complications in cancer patients, has been linked to a rare and life-threatening metabolic crisis characterized by profound mineral depletion. A landmark case study published in JCEM Case Reports details a "hungry bone syndrome-like state" occurring in a 76-year-old male with multiple myeloma, a…
